Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xolair in moderate to severe persistent asthma (EXTRA)
NCT00314574Phase 3Completed
- Sponsor
- Genentech
- Start
- Dec 2005
- Primary completion
- Nov 2009
01
Overview
Phase 3, randomised, double-blind trial in asthma comparing Xolair + ICS + LABA with Placebo + ICS + LABA (2 arms). Primary endpoint: Rate of Asthma Exacerbations at 48 weeks. Started Dec 2005; status: completed.
02
Drugs
omalizumab
03
Conditions
asthma
Beyond the preview
Go deeper on NCT00314574.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00314574.